Scrip's Five Must-Know Things - Sept, 14, 2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity.

Story links: insights.citeline.com/scrip/podcasts/scrips-fi…

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts (podcasts.apple.com/us/podcast/scrip-podcasts/i…), and Spotify Podcasts (open.spotify.com/show/54Ki1l5bTzuxvrUylwbvO9?s…)and on TuneIn (tunein.com/podcasts/Business--Economics-Podcas…).

Contact us on podcasts@norstella.com.